Home Healthcare Pharmaceuticals Urinary Tract Infection Therapeutics Market

Urinary Tract Infection Therapeutics Market Size, Share & Trends Analysis Report By Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, Other Drugs), By Indication (Complicated UTI, Uncomplicated UTI, Other Indications) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Debashree B | Format: | Report Code: SR3324DR | Pages: 150
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Urinary Tract Infection Therapeutics Market, By Drug 2022-2034 (USD MILLION/ Units)
    1. Penicillin and Combinations
    2. Quinolones
    3. Cephalosporin
    4. Azoles and Amphotericin B
    5. Nitrofurans
    6. Other Drugs
  2. Urinary Tract Infection Therapeutics Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Complicated UTI
    2. Uncomplicated UTI
    3. Other Indications
  3. Regional Urinary Tract Infection Therapeutics Market
    1. North America
      1. North America Urinary Tract Infection Therapeutics Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
      2. North America Urinary Tract Infection Therapeutics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Complicated UTI
        2. Uncomplicated UTI
        3. Other Indications
      3. U.S.
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      4. Canada
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
    2. Europe
      1. Europe Urinary Tract Infection Therapeutics Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
      2. Europe Urinary Tract Infection Therapeutics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Complicated UTI
        2. Uncomplicated UTI
        3. Other Indications
      3. U.K.
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      4. Germany
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      5. France
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      6. Spain
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      7. Italy
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      8. Russia
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      9. Nordic
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      10. Benelux
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      11. Rest of Europe
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
    3. APAC
      1. APAC Urinary Tract Infection Therapeutics Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
      2. APAC Urinary Tract Infection Therapeutics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Complicated UTI
        2. Uncomplicated UTI
        3. Other Indications
      3. China
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      4. Korea
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      5. Japan
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      6. India
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      7. Australia
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      8. Taiwan
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      9. South East Asia
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      10. Rest of Asia-Pacific
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
    4. Middle East and Africa
      1. Middle East and Africa Urinary Tract Infection Therapeutics Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
      2. Middle East and Africa Urinary Tract Infection Therapeutics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Complicated UTI
        2. Uncomplicated UTI
        3. Other Indications
      3. UAE
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      4. Turkey
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      5. Saudi Arabia
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      6. South Africa
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      7. Egypt
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      8. Nigeria
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      9. Rest of MEA
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
    5. LATAM
      1. LATAM Urinary Tract Infection Therapeutics Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
      2. LATAM Urinary Tract Infection Therapeutics Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Complicated UTI
        2. Uncomplicated UTI
        3. Other Indications
      3. Brazil
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      4. Mexico
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      5. Argentina
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      6. Chile
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      7. Colombia
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
      8. Rest of LATAM
        1. Penicillin and Combinations
        2. Quinolones
        3. Cephalosporin
        4. Azoles and Amphotericin B
        5. Nitrofurans
        6. Other Drugs
        7. Complicated UTI
        8. Uncomplicated UTI
        9. Other Indications
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.